Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply for ...

Novo’s GLP-1 drugs have semaglutide as their active ingredient, while Lilly has tirzepatide. These GLP-1 treatments have grown to account for the largest portions of revenues.

Novo Nordisk's late stage diabetes candidate semaglutide has scored another victory, outperforming Eli Lilly’s Trulicity in controlling glucose levels and body weight. The phase 3 trial success ...

Teladoc Health has partnered with Eli Lilly’s LillyDirect and pharmacy provider GiftHealth to expand access to Zepbound, a GLP-1 drug prescribed for weight loss. The partnership allows Teladoc ...

Citi reiterated a Buy rating and $1,190 price target on Eli Lilly (LLY), saying the firm expects a positive read-through to the shares on FDA’s statement highlighting its concerns with ...

An Eli Lilly exec said the company’s experimental weight-loss pillcould make GLP-1 treatments more accessible worldwide, as it would be easier to manufacture and distribute globally.

When it comes to clinical weight-loss treatments, GLP-1 therapies have taken the medical sector by storm. What started as off-label use by celebrities and social media influencers for cutting ...